País: Canadà
Idioma: anglès
Font: Health Canada
ENTECAVIR (ENTECAVIR MONOHYDRATE)
ACCEL PHARMA INC
J05AF10
ENTECAVIR
0.5MG
TABLET
ENTECAVIR (ENTECAVIR MONOHYDRATE) 0.5MG
ORAL
30
Prescription
NUCLEOSIDES AND NUCLEOTIDES
Active ingredient group (AIG) number: 0151648001; AHFS:
APPROVED
2018-08-16
_Accel-Entecavir _ _Page 1 of 40 _ PRODUCT MONOGRAPH Pr ACCEL-ENTECAVIR Entecavir Tablets 0.5 mg Antiviral Accel Pharma Inc. 99 Place Frontenac Pointe-Claire, Quebec H9R 4Z7 DATE OF REVISION: June 21, 2019 Control No. 227796 _Accel-Entecavir _ _Page 2 of 40 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................................................... 3 CONTRAINDICATIONS .............................................................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................................................ 3 ADVERSE REACTIONS .............................................................................................................................. 6 DRUG INTERACTIONS ............................................................................................................................... 9 DOSAGE AND ADMINISTRATION ......................................................................................................... 10 OVERDOSAGE ........................................................................................................................................... 11 STORAGE AND STABILITY .................................................................................................................... 17 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................................................ 17 PART II: SCIENTIFIC INFORMATION ........................................................................................................... 18 PHARMACEUTICAL INFORMATION ................................................................................ Llegiu el document complet